July 26 (Reuters) - Cosmo Pharmaceuticals Nv COPN.S :
* COSMO PRESENTS STRONG H1 2023 OPERATIONAL AND FINANCIAL
RESULTS
* H1 PRETAX PROFIT 3.7 MILLION EUR VERSUS 9.1 MILLION EUR
YEAR AGO
* H1 EBITDA 14.0 MILLION EUR VERSUS 14.9 MILLION EUR YEAR
AGO
* H1 OPERATING PROFIT 7.1 MILLION EUR VERSUS 8.1 MILLION EUR
YEAR
AGO
* H1 REVENUE 43.7 MILLION EUR VERSUS 41.5 MILLION EUR YEAR
AGO
* REAFFIRMATION OF FY 2023 GUIDANCE OF TOTAL REVENUES IN
RANGE OF
EUR 110 MILLION - EUR 120 MILLION
* REAFFIRMATION OF FY 2023 GUIDANCE OF OPERATING PROFIT IN
RANGE
OF EUR 25 MILLION - EUR 35 MILLION
Source text for Eikon: ID:nEQ8dxJ74a
Further company coverage: COPN.S
((Reuters.Briefs@thomsonreuters.com;))